Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (2681I)
20 Mars 2018 - 10:15AM
UK Regulatory
TIDMHCM
RNS Number : 2681I
Hutchison China Meditech Limited
20 March 2018
Grant of Share Options under Share Option Scheme
London: Tuesday, March 20, 2018: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 19,
2018, it granted share options under the Share Option Scheme
adopted by Chi-Med at its Annual General Meeting on April 24, 2015
(the "Share Option Scheme").
Chi-Med granted 150,000 share options under its Share Option
Scheme to certain employees to subscribe for Ordinary Shares
subject to the acceptance of the grantees. Details of such share
options granted prescribed are as follows:
Date of grant : March 19, 2018
Exercise price of share : GBP49.74 per Ordinary Share
options granted
Number of share options : 150,000 (each share option
granted shall entitle the holder
thereof to subscribe for
one Ordinary Share)
Closing market price : GBP48.45 per Ordinary Share
of Ordinary Shares on
the date of grant
Validity period of the : From March 19, 2018 to March
share options 18, 2028
100,000 of the 150,000 share options were granted to Dr Weiguo
Su, Executive Director and Chief Scientific Officer, being a person
discharging managerial responsibility under the EU Market Abuse
Regulation.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Dr Weiguo Su
------------------------------------------------------- -----------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------------------------------
a) Position/status Executive Director and Chief Scientific Officer
------------------------------------------------------- -----------------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
--------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
------------------------------------------------------- -----------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
------------------------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
--------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of Option over Ordinary Share of US$1.00
instrument
Identification code
Option over Ordinary Share with DI ISIN:
KYG4672N1016
------------------------------------------------------- -----------------------------------------------------
b) Nature of the transaction Grant of options in respect of 100,000 Ordinary
Shares under the Share Option Scheme.
The share options granted are exercisable subject
to a vesting schedule of 25% on each of
the first, second, third and fourth anniversaries
of the effective date of grant.
------------------------------------------------------- -----------------------------------------------------
Price(s) Volume(s)
c) Price(s) and volume(s) Nil 100,000
-------------------
------------------------------------------------------- -----------------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------------------------------- -----------------------------------------------------
e) Date of the transaction 2018-03-19
------------------------------------------------------- -----------------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------------------------- -----------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance
& Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHPGUQAWUPRURU
(END) Dow Jones Newswires
March 20, 2018 05:15 ET (09:15 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024